AR041374A1 - Derivados de 2-oxodihidropiridina n- sustituidos - Google Patents
Derivados de 2-oxodihidropiridina n- sustituidosInfo
- Publication number
- AR041374A1 AR041374A1 ARP030103473A ARP030103473A AR041374A1 AR 041374 A1 AR041374 A1 AR 041374A1 AR P030103473 A ARP030103473 A AR P030103473A AR P030103473 A ARP030103473 A AR P030103473A AR 041374 A1 AR041374 A1 AR 041374A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- alkylamino
- alkylcarbamoyl
- alkoxy
- hydroxy
- Prior art date
Links
- 125000000217 alkyl group Chemical group 0.000 abstract 9
- 125000005115 alkyl carbamoyl group Chemical group 0.000 abstract 6
- 125000003545 alkoxy group Chemical group 0.000 abstract 5
- 125000003282 alkyl amino group Chemical group 0.000 abstract 4
- 229910052736 halogen Inorganic materials 0.000 abstract 4
- 150000002367 halogens Chemical group 0.000 abstract 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 4
- 125000005236 alkanoylamino group Chemical group 0.000 abstract 3
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 3
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 abstract 3
- 125000004414 alkyl thio group Chemical group 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 208000032841 Bulimia Diseases 0.000 abstract 1
- 206010006550 Bulimia nervosa Diseases 0.000 abstract 1
- 108050002826 Neuropeptide Y Receptor Proteins 0.000 abstract 1
- 102000012301 Neuropeptide Y receptor Human genes 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 abstract 1
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 125000004657 aryl sulfonyl amino group Chemical group 0.000 abstract 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 abstract 1
- 125000004104 aryloxy group Chemical group 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 125000001589 carboacyl group Chemical group 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- -1 ester salt Chemical class 0.000 abstract 1
- 125000004438 haloalkoxy group Chemical group 0.000 abstract 1
- 125000001188 haloalkyl group Chemical group 0.000 abstract 1
- 125000005553 heteroaryloxy group Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
- C07D213/80—Acids; Esters in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Un compuesto de fórmula (1), (donde Ar1 y Ar2 son, de modo independiente, arilo o heteroarilo, cualquiera de los cuales está opcionalmente sustituido por un sustituyente seleccionado del grupo integrado por ciano, halógeno, nitro, alquilo inferior,halo-alquilo inferior, hidroxi-alquilo inferior, ciclo-alquilo inferior, ciclo(alquil inferior)-alquilo, inferior, alquenilo inferior, alquilamino inferior, di-alquilamino inferior, alcanoilamino inferior, alquilsulfonilamino inferior,arilsulfonilamino, hidroxi, alcoxi inferior, halo-alcoxi inferior, ariloxi, heteroariloxi, alquiltio inferior, carboxilo. formilo, alcanoilo inferior, alcoxicarbonilo inferior, carbamoilo, alquilcarbamoilo inferior, di-alquilcarbamoilo inferior,alquilsulfonilo inferior, arilsulfonilo, arilo y heteroarilo; R1 y R2 son, de modo independiente, alquilo inferior, ciclo-alquilo inferior, ciclo(alquil inferior)-alquilo inferior o alcoxi inferior, cualquiera de los cuales está opcionalmentesustituido por un sustituyente seleccionado del grupo integrado por halógeno, alquilamino inferior, di-alquilamino inferior, alcanoilamino inferior, hidroxi, alcoxi inferior, formilo, alcoxicarbonilo inferior, alquilcarbamoilo inferior ydi-alquilcarbamoilo inferior; R3, R4 y R5 son, de modo independiente, hidrógeno, ciano, halógeno o hidroxi, o alquilo inferior, alcoxi inferior o alquiltio inferior, estando los últimos tres grupos opcionalmente sustituidos por un sustituyenteseleccionado del grupo integrado por halógeno, alquilamino inferior, di-alquilamino inferior, alcanoilamino inferior, hidroxi, alcoxi inferior, formilo, alcoxicarbonilo inferior, alquilcarbamoilo inferior y di-alquilcarbamoilo inferior), o una sal oéster de los mismos, es útil como agente antagonista del receptor del neuropéptido Y, y también es útil como agente para el tratamiento de bulimia, obesidad o diabetes.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2002287015 | 2002-09-30 | ||
| JP2002353202 | 2002-12-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR041374A1 true AR041374A1 (es) | 2005-05-11 |
Family
ID=32072466
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP030103473A AR041374A1 (es) | 2002-09-30 | 2003-09-24 | Derivados de 2-oxodihidropiridina n- sustituidos |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US6869966B2 (es) |
| EP (1) | EP1546133B1 (es) |
| KR (1) | KR20050059217A (es) |
| CN (1) | CN100528864C (es) |
| AR (1) | AR041374A1 (es) |
| AT (1) | ATE461191T1 (es) |
| AU (1) | AU2003273522B2 (es) |
| BR (1) | BR0314965A (es) |
| CA (2) | CA2497237C (es) |
| DE (1) | DE60331751D1 (es) |
| MX (1) | MXPA05003293A (es) |
| NO (1) | NO20052106L (es) |
| PE (1) | PE20050087A1 (es) |
| PL (1) | PL376475A1 (es) |
| RU (1) | RU2005113310A (es) |
| TW (1) | TW200407138A (es) |
| WO (1) | WO2004031175A2 (es) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040242566A1 (en) * | 2003-03-25 | 2004-12-02 | Syrrx, Inc. | Dipeptidyl peptidase inhibitors |
| EP1625122A1 (en) | 2003-05-14 | 2006-02-15 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
| US7678909B1 (en) | 2003-08-13 | 2010-03-16 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| US7169926B1 (en) | 2003-08-13 | 2007-01-30 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| CA2535619A1 (en) * | 2003-08-13 | 2005-02-24 | Takeda Pharmaceutical Company Limited | 4-pyrimidone derivatives and their use as peptidyl peptidase inhibitors |
| EP1697342A2 (en) * | 2003-09-08 | 2006-09-06 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| JP2007505121A (ja) * | 2003-09-08 | 2007-03-08 | 武田薬品工業株式会社 | ジペプチジルぺプチダーゼ阻害剤 |
| FR2861303A1 (fr) * | 2003-10-24 | 2005-04-29 | Sanofi Synthelabo | Utilisation d'un derive de pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique |
| FR2861302A1 (fr) * | 2003-10-24 | 2005-04-29 | Sanofi Synthelabo | Utilisation d'un derive du pyrazole, pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique. |
| FR2861301B1 (fr) * | 2003-10-24 | 2008-07-11 | Sanofi Synthelabo | Utilisation du derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique. |
| FR2861300B1 (fr) * | 2003-10-24 | 2008-07-11 | Sanofi Synthelabo | Utilisation d'un derive du pyrazole, pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique |
| US7732446B1 (en) | 2004-03-11 | 2010-06-08 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| GEP20094679B (en) * | 2004-03-15 | 2009-05-10 | Takeda Pharmaceuticals Co | Dipeptidyl peptidase inhibitors |
| US7838552B2 (en) | 2004-06-04 | 2010-11-23 | Forest Laboratories Holdings Limited | Compositions comprising nebivolol |
| US7803838B2 (en) | 2004-06-04 | 2010-09-28 | Forest Laboratories Holdings Limited | Compositions comprising nebivolol |
| US7687638B2 (en) * | 2004-06-04 | 2010-03-30 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
| JP4675586B2 (ja) * | 2004-06-23 | 2011-04-27 | 壽製薬株式会社 | 高血圧症及び血清高尿酸血症の重複発症の治療のための薬剤 |
| WO2006019965A2 (en) | 2004-07-16 | 2006-02-23 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
| US7872124B2 (en) * | 2004-12-21 | 2011-01-18 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| CN101309689B (zh) * | 2005-09-14 | 2012-10-10 | 武田药品工业株式会社 | 用于治疗糖尿病的二肽基肽酶抑制剂 |
| ME02005B (me) | 2005-09-14 | 2012-08-31 | Takeda Pharmaceuticals Co | Inhibitori dipeptidil peptidaze za lečenje dijabetesa |
| CN101360723A (zh) * | 2005-09-16 | 2009-02-04 | 武田药品工业株式会社 | 制备嘧啶二酮衍生物的方法 |
| TW200745079A (en) * | 2005-09-16 | 2007-12-16 | Takeda Pharmaceuticals Co | Polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and methods of use therefor |
| TW200745080A (en) * | 2005-09-16 | 2007-12-16 | Takeda Pharmaceuticals Co | Polymorphs of tartrate salt of 2-[2-(3-(R)-amino-piperidin-1-yl)-5-fluoro-6-oxo-6H-pyrimidin-1-ylmethyl]-benzonitrile and methods of use therefor |
| CN101277960A (zh) | 2005-09-29 | 2008-10-01 | 默克公司 | 作为黑皮质素-4受体调节剂的酰化螺哌啶衍生物 |
| WO2007112347A1 (en) | 2006-03-28 | 2007-10-04 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| JP2009531456A (ja) * | 2006-03-28 | 2009-09-03 | 武田薬品工業株式会社 | （ｒ）−３−アミノピペリジン二塩酸塩の調製 |
| WO2007115967A1 (en) * | 2006-04-12 | 2007-10-18 | F. Hoffmann-La Roche Ag | Crystalline isopropanol solvate of glucokinase activator |
| US8324383B2 (en) | 2006-09-13 | 2012-12-04 | Takeda Pharmaceutical Company Limited | Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile |
| EP2698157B1 (en) | 2006-09-22 | 2015-05-20 | Merck Sharp & Dohme Corp. | Method of treatment using fatty acid synthesis inhibitors |
| TW200838536A (en) * | 2006-11-29 | 2008-10-01 | Takeda Pharmaceutical | Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor |
| US8093236B2 (en) | 2007-03-13 | 2012-01-10 | Takeda Pharmaceuticals Company Limited | Weekly administration of dipeptidyl peptidase inhibitors |
| JP5319518B2 (ja) | 2007-04-02 | 2013-10-16 | Ｍｓｄ株式会社 | インドールジオン誘導体 |
| AU2009308980B2 (en) | 2008-10-30 | 2013-02-28 | Merck Sharp & Dohme Corp. | Isonicotinamide orexin receptor antagonists |
| AR088352A1 (es) | 2011-10-19 | 2014-05-28 | Merck Sharp & Dohme | Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina |
| TWI762806B (zh) * | 2014-04-09 | 2022-05-01 | 美商建南德克公司 | 作為ｅｒｋ抑制劑之化合物 |
| CN109369538B (zh) * | 2018-11-30 | 2021-01-22 | 华南农业大学 | 一种n-二氟甲基唑类硫(硒)脲衍生物及其制备方法 |
| US11098029B2 (en) | 2019-02-13 | 2021-08-24 | Merck Sharp & Dohme Corp. | 5-alkyl pyrrolidine orexin receptor agonists |
| US12331018B2 (en) | 2019-02-13 | 2025-06-17 | Merck Sharp & Dohme Llc | Pyrrolidine orexin receptor agonists |
| WO2021026047A1 (en) | 2019-08-08 | 2021-02-11 | Merck Sharp & Dohme Corp. | Heteroaryl pyrrolidine and piperidine orexin receptor agonists |
| MX2023001840A (es) | 2020-08-18 | 2023-03-13 | Merck Sharp & Dohme Llc | Agonistas de bicicloheptano pirrolidina de los receptores de orexina. |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH234887A (de) * | 1942-12-11 | 1944-10-31 | Ag J R Geigy | Verfahren zur Herstellung von N-Cyclohexyl-6-pyridon-3-carbonsäurediäthylamid. |
| CZ403592A3 (en) * | 1992-02-20 | 1993-12-15 | Hoechst Ag | Arylcarbonylaminoalkyldihydrooxopyridines, process of their preparation and their use |
| AU757488B2 (en) | 1998-03-25 | 2003-02-20 | Bristol-Myers Squibb Company | Imidazolone anorectic agents: III. heteroaryl derivatives |
| AU2001234128B2 (en) * | 2000-02-22 | 2004-11-11 | Banyu Pharmaceutical Co., Ltd. | Novel imidazoline compounds |
-
2003
- 2003-08-15 US US10/641,017 patent/US6869966B2/en not_active Expired - Fee Related
- 2003-09-17 TW TW092125570A patent/TW200407138A/zh unknown
- 2003-09-22 PE PE2003000968A patent/PE20050087A1/es not_active Application Discontinuation
- 2003-09-24 AR ARP030103473A patent/AR041374A1/es unknown
- 2003-09-25 PL PL03376475A patent/PL376475A1/xx not_active Application Discontinuation
- 2003-09-25 WO PCT/JP2003/012290 patent/WO2004031175A2/en not_active Ceased
- 2003-09-25 KR KR1020057005511A patent/KR20050059217A/ko not_active Withdrawn
- 2003-09-25 MX MXPA05003293A patent/MXPA05003293A/es unknown
- 2003-09-25 CA CA2497237A patent/CA2497237C/en not_active Expired - Fee Related
- 2003-09-25 EP EP03755682A patent/EP1546133B1/en not_active Expired - Lifetime
- 2003-09-25 AT AT03755682T patent/ATE461191T1/de not_active IP Right Cessation
- 2003-09-25 AU AU2003273522A patent/AU2003273522B2/en not_active Ceased
- 2003-09-25 RU RU2005113310/04A patent/RU2005113310A/ru not_active Application Discontinuation
- 2003-09-25 BR BR0314965-0A patent/BR0314965A/pt not_active Application Discontinuation
- 2003-09-25 CA CA2726754A patent/CA2726754C/en not_active Expired - Fee Related
- 2003-09-25 CN CNB038233398A patent/CN100528864C/zh not_active Expired - Fee Related
- 2003-09-25 DE DE60331751T patent/DE60331751D1/de not_active Expired - Lifetime
-
2004
- 2004-07-27 US US10/899,162 patent/US7138525B2/en not_active Expired - Fee Related
-
2005
- 2005-04-29 NO NO20052106A patent/NO20052106L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PE20050087A1 (es) | 2005-02-22 |
| TW200407138A (en) | 2004-05-16 |
| DE60331751D1 (de) | 2010-04-29 |
| US20040072874A1 (en) | 2004-04-15 |
| CN100528864C (zh) | 2009-08-19 |
| WO2004031175A3 (en) | 2005-02-24 |
| BR0314965A (pt) | 2005-08-02 |
| US6869966B2 (en) | 2005-03-22 |
| CA2726754C (en) | 2013-04-02 |
| CA2497237C (en) | 2011-03-29 |
| ATE461191T1 (de) | 2010-04-15 |
| NO20052106L (no) | 2005-04-29 |
| CA2497237A1 (en) | 2004-04-15 |
| PL376475A1 (en) | 2005-12-27 |
| EP1546133A2 (en) | 2005-06-29 |
| US20050009879A1 (en) | 2005-01-13 |
| EP1546133B1 (en) | 2010-03-17 |
| MXPA05003293A (es) | 2005-10-18 |
| AU2003273522B2 (en) | 2009-05-21 |
| KR20050059217A (ko) | 2005-06-17 |
| CN1684954A (zh) | 2005-10-19 |
| RU2005113310A (ru) | 2005-11-10 |
| US7138525B2 (en) | 2006-11-21 |
| AU2003273522A1 (en) | 2004-04-23 |
| WO2004031175A2 (en) | 2004-04-15 |
| CA2726754A1 (en) | 2004-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR041374A1 (es) | Derivados de 2-oxodihidropiridina n- sustituidos | |
| BRPI0411365A (pt) | derivados de aminopiridina | |
| EA200600317A1 (ru) | Производные омега-карбоксиарилдифенилмочевины (варианты), фармацевтическая композиция (варианты) и способ лечения и предупреждения заболеваний и состояний с их использованием (варианты) | |
| PA8556201A1 (es) | Alquinos como inhibidores de metaloproteinasa de matriz | |
| PA8571001A1 (es) | 2-(2,6-diclorofenil)-diarilimidazoles | |
| CU23550B7 (es) | Derivados de pirrolo-pirazol sustituidos como inhibidores de quinasa | |
| ECSP034809A (es) | Ciclobuteno-1,2-dionas 3,4-disustituidas como ligandos del receptor de quimocina cxc | |
| CY1106358T1 (el) | Νεοι δικυκλικοι αναστολεις της ορμονοευαισθητης λιπασης | |
| EA200401194A1 (ru) | Миметики глюкокортикоидов, способы их получения, фармацевтические композиции и их применение | |
| CO5550451A2 (es) | Derivados de 3-(sulfonamidoetil)-indol para uso como mimeti- cos de glucocorticoides en el tratamiento de enfermedades inflamatorias, alergicas y proliferativas | |
| NO20054082L (no) | Pyrazol`1,5-A! 1,3,5! triazinderivater som kannabinoidreseptorligander | |
| NO20021358L (no) | Alkylendiamin-substituerte heterocykler | |
| AU2003226572A1 (en) | Heteroaryl substituted biphenyl derivatives as p38 kinase inhibitors | |
| ATE302775T1 (de) | Carbolinderivate | |
| ECSP055582A (es) | Derivados de benzotiazol que tienen actividad agonista de beta-2-adrenorreceptor | |
| ECSP066886A (es) | Compuestos y métodos para el tratamiento de dislipidemia | |
| PA8680701A1 (es) | Derivados de oxindol | |
| CY1113924T1 (el) | Ενωσεις καρβαζολης και θεραπευτικες χρησεις των ενωσεων | |
| NO20060665L (no) | N-substituerte pyrazolyl-amidyl-benzimidazolyl C-kit inhibitorer | |
| NO20072344L (no) | Trombineresptorantagonister. | |
| CR7566A (es) | Derivados de 1-(aminoalquil)-3-sulfonilindol y 1-aminoalquil-3-sulfonilindazol como ligandos de 5-hidroxitriptamina-6 | |
| BR0309278A (pt) | Composto, composição, métodos para modular a atividade da cinesina ksp, para inibir a ksp, para o tratamento de uma doença proliferativa celular, e, uso de um composto | |
| NO20060670L (no) | N3-substituerte imidazopyridin C-kit inhibitorer | |
| DK1643984T3 (da) | Anvendelse af parthenolidderivater som antileukæmiske og cytotoksske midler | |
| NO20060195L (no) | Kinolylamidderivater som CCR-5-antagonister |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |